Vical cuts 47 workers after recent Allovectin failure
This article was originally published in Scrip
Vical will lay off 47 employees, cutting its work force by 39%, to focus on infectious disease vaccine programs following the recent Phase III failure of the intratumoral cancer immunotherapy Allovectin (velimogene aliplasmid) for metastatic melanoma.
You may also be interested in...
New report shows average out-of-pocket cost per prescription of $10.67 in 2019 was unchanged from 2018. But while the number of dispensed drugs barely increased, sales jumped more than 5%.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.
The expectation of a big second quarter sales decline proved true, but the situation is improving. Meanwhile, Merck & Co. is advancing two vaccines and an antiviral against the novel coronavirus.